{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:29:47Z","timestamp":1793658587590,"version":"4.5.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Matt Mullenweg, Craig Nerenberg, Blake Mycoskie, Steven and Alexandra Cohen Foundation. Dr. Ehrenkranz is supported by funds from Sunstone Therapies"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Recent discussions about the methodological rigor of psychedelic clinical trials have focused on potential underreporting or misreporting of adverse events (AEs), with many calling for their systematic assessment to help mitigate these issues. In their recent paper, Palitsky et al. offer a comprehensive framework for the assessment of AEs in psychedelic-assisted therapies, with consideration of the spiritual, existential, religious, and theological impacts that psychedelics can have. In this commentary, we respond to Palitsky et al.\u2019s proposal, discussing the framework, its feasibility, and various assessment methods. We emphasize the need to ensure that AE assessment in psychedelic clinical trials is held to the same rigor and standard as research in other areas, in addition to maintaining and improving transparency and accessibility in AE reporting.<\/jats:p>","DOI":"10.1177\/02698811241309623","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T23:47:18Z","timestamp":1735516038000},"page":"431-433","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Commentary: A framework for assessment of adverse events in psychedelic research"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3529-4109","authenticated-orcid":false,"given":"Katherine","family":"Cheung","sequence":"first","affiliation":[{"name":"Bloomberg School of Public Health and Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ehrenkranz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine School of Medicine, Center for Psychedelic and Consciousness Research, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared T","family":"Hinkle","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine School of Medicine, Center for Psychedelic and Consciousness Research, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Yaden","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine School of Medicine, Center for Psychedelic and Consciousness Research, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"e_1_3_2_2_1","first-page":"1","article-title":"Eliciting adverse effects data from participants in clinical trials","author":"Allen EN","year":"2018","unstructured":"Allen EN, Chandler CI, Mandimika N, et al. (2018) Eliciting adverse effects data from participants in clinical trials. Cochr Database Syst Rev: 1\u201385.","journal-title":"Cochr Database Syst Rev"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221116926"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.08.091"},{"key":"e_1_3_2_5_1","article-title":"Distinctive but not exceptional: Against psychedelic ethical exceptionalism","author":"Cheung K","unstructured":"Cheung K, Earp BD, Patch K, et al. (in press) Distinctive but not exceptional: Against psychedelic ethical exceptionalism. Am J Bioethics.","journal-title":"Am J Bioethics"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291723001058"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2024.0006"},{"key":"e_1_3_2_8_1","unstructured":"FDA. (2023). Psychedelic drugs: Considerations for clinical investigations. Guidance for Industry. Available at: https:\/\/www.fda.gov\/media\/169694\/download"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2024.2342764"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13370"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0099"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241265756"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000177129"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211069100"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231198466"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44159-024-00345-6"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241309623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811241309623","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241309623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:02Z","timestamp":1777507922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811241309623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/02698811241309623"],"URL":"https:\/\/doi.org\/10.1177\/02698811241309623","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}